(New Title) establishing a medical psilocybin advisory board to assess the advantages and disadvantages of the use of psilocybin for therapeutic purposes.

Sponsors & Cosponsors

Roll Call Votes

No roll call votes available for this bill.

Actions Timeline

1. Committee Report: Inexpedient to Legislate, 05/07/2026, Vote 4-0, CC; SC 17

   4/23/2026Senate

2. Hearing: 04/08/2026, Room 100, SH, 09:45 am; SC 13

   4/1/2026Senate

3. Introduced 03/26/2026 and Referred to Health and Human Services; SJ 7

   3/30/2026Senate

4. Ought to Pass with Amendment 2026-1201h: MA VV 03/26/2026 HJ 9

   3/26/2026House

5. Amendment # 2026-1201h (NT): AA DV 248-101 03/26/2026 HJ 9

   3/26/2026House

6. Inexpedient to Legislate: MF DV 127-222 03/26/2026 HJ 9

   3/26/2026House

7. Minority Committee Report: Ought to Pass with Amendment # 2026-1201h (NT)

   3/19/2026House

8. Majority Committee Report: Inexpedient to Legislate 03/17/2026 (Vote 13-11; RC)

   3/19/2026House

9. Executive Session: 03/17/2026 10:00 am GP 230

   3/13/2026House

10. Division III Work Session: 03/13/2026 09:00 am GP 234

    3/9/2026House

11. Referred to Finance 02/12/2026 HJ 4 P. 7

    2/12/2026House

12. Ought to Pass: MA VV 02/12/2026 HJ 4 P. 7

    2/12/2026House

13. Committee Report: Ought to Pass 01/28/2026 (Vote 18-0; CC) HC 6 P. 7

    2/3/2026House

14. Executive Session: 01/28/2026 02:30 pm GP 158

    1/21/2026House

15. Public Hearing: 01/14/2026 03:00 pm GP 158

    1/8/2026House

16. Introduced 01/07/2026 and referred to Health, Human Services and Elderly Affairs HJ 1 P. 37

    12/18/2025House

Bill Text

• Introduced

  12/18/2025

  PDF